Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study

医学 免疫性血小板减少症 不利影响 内科学 免疫系统 打开标签 免疫学 抗体
作者
Peng Zhao,Zhuo‐Yu An,Haixia Fu,Hui‐Xin Liu,Chengjie Feng,Qiu‐Sha Huang,Jin Wu,Yejun Wu,Liping Yang,Qingyuan Qu,Yuxiu Chen,Menglin Li,Chen‐Cong Wang,Qi Chen,Xiaolu Zhu,Yun He,Yuanyuan Zhang,Qian Jiang,Hao Jiang,Jin Lü
出处
期刊:American Journal of Hematology [Wiley]
卷期号:99 (10): 1951-1958 被引量:3
标识
DOI:10.1002/ajh.27433
摘要

Abstract Patients with steroid‐resistant or relapsed immune thrombocytopenia (ITP) suffer increased bleeding risk and impaired quality of life. Baricitinib, an oral Janus‐associated kinases (JAK) inhibitor, could alleviate both innate and adaptive immune disorders without inducing thrombocytopenia in several autoimmune diseases. Accordingly, an open‐label, single‐arm, phase 2 trial (NCT05446831) was initiated to explore the safety and efficacy of baricitinib in ITP. Eligible patients were adults with primary ITP who were refractory to corticosteroids and at least one subsequent treatment, and had platelet counts below 30 × 10 9 /L at enrolment. Participants received baricitinib 4 mg daily for 6 months. The primary endpoint was durable response at the 6‐month follow‐up. A total of 35 patients were enrolled. Durable response was achieved in 20 patients (57.1%, 95% confidence interval, 39.9 to 74.4), and initial response in 23 (65.7%) patients. For patients responding to baricitinib, the median time to response was 12 (IQR 6–20) days, and the median peak platelet count was 94 (IQR 72–128) × 10 9 /L. Among the 27 patients undergoing extend observation, 12 (44.4%) remained responsive for a median duration of approximately 20 weeks after baricitinib discontinuation. Adverse events were reported in 11 (31.4%) patients, including infections in 6 (17.1%) patients during the treatment period. Treatment discontinuation due to an adverse event was reported in 2 (5.7%) patients. Evidence from this pilot study suggested that baricitinib might be a novel candidate for the armamentarium of ITP‐modifying agents. Future studies are warranted to validate the safety, efficacy, and optimal dosing of baricitinib in patients with ITP.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ty发布了新的文献求助10
1秒前
Rollei完成签到,获得积分10
2秒前
光光发电完成签到,获得积分10
2秒前
蓑衣客完成签到,获得积分10
6秒前
6秒前
木青仙子完成签到,获得积分10
8秒前
小蘑菇应助给他来个地瓜采纳,获得10
8秒前
科研通AI2S应助sukuyo采纳,获得10
11秒前
慕青应助哎吆歪采纳,获得10
15秒前
晨曦完成签到,获得积分10
15秒前
研友_VZG7GZ应助只因采纳,获得10
16秒前
16秒前
沉默的寻凝完成签到 ,获得积分10
17秒前
OAO完成签到,获得积分10
18秒前
暴富完成签到,获得积分10
19秒前
OAO发布了新的文献求助30
21秒前
赘婿应助祝您发财采纳,获得10
22秒前
微笑的若魔完成签到 ,获得积分10
23秒前
WLWLW应助金熙美采纳,获得10
23秒前
23秒前
23秒前
24秒前
圆蓬蓬完成签到,获得积分10
24秒前
烟花应助wjfan采纳,获得10
24秒前
一大意完成签到,获得积分10
25秒前
imzmy完成签到,获得积分10
25秒前
思源应助Uload采纳,获得10
26秒前
26秒前
圆蓬蓬发布了新的文献求助10
26秒前
27秒前
CC悟了发布了新的文献求助10
29秒前
乐乐应助北彧采纳,获得10
29秒前
打打应助三笠采纳,获得10
29秒前
30秒前
30秒前
猫南北发布了新的文献求助50
30秒前
肥四完成签到,获得积分10
31秒前
31秒前
drfwjuikesv应助科研爱好者采纳,获得10
32秒前
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975722
求助须知:如何正确求助?哪些是违规求助? 3520056
关于积分的说明 11200719
捐赠科研通 3256455
什么是DOI,文献DOI怎么找? 1798271
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390